Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the study is to investigate the impact of time to closed reduction on both patient related and organizational factors. These include, length of stay, hospitalization, admission to intensive care unit, rehospitalizations, delirium, all-cause mortality, infection requiring hospital contact, and cardiovascular complications. It is also intended to investigate whether different anaesthetic strategies and airway management are associated with different complication rates.
It is hypothesized that longer waiting time until reduction increase the postoperative length of stay, readmissions, and risk of complications.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patients underwent closed reduction of dislocated THA | adults presenting with a dislocated THA, who underwent closed reduction in an operating theatre with anesthesiology being involved, in public hospitals |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Time in minutes from admission to closed reduction | Other | Time in minutes from admission to closed reduction measured as: From arriving time in the emergency department until the start of surgery in the operating theater. |
| Measure | Description | Time Frame |
|---|---|---|
| Post procedure length of stay | Post procedure length of stay from closed reduction until discharge from the hospital (hours) | 30 days after the closed reduction |
| Measure | Description | Time Frame |
|---|---|---|
| All-cause mortality | 90 days all-cause mortality (Y/N) | 90 days after closed reduction |
| Admissions to Intensive care unit | Admissions to the intensive care unit within 30 days after the closed reduction. |
Not provided
Inclusion Criteria:
Patients will be considered eligible for inclusion if they meet all of the following criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The cohort contains all adults presenting with a dislocated THA, who underwent closed reduction in an operating theatre with anesthesiology being involved, in public hospitals in the Capital and Zealand Regions of Denmark.
The study population is extracted from a dataset retrieved from the Electronic Health Record (EHR) system 'Sundhedsplatformen' (Epic Systems Corporation, WI, USA) from 1 January 2017 to 31 December 2024, including granular data from approximately 1.1 million anesthetic procedures
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lars H Lundstrøm, MD, PhD | Contact | +4548296512 | lars.hyldborg.lundstroem.02@regionh.dk | |
| Rikke HF Bjulf, Research fellow | Contact | +4548292244 | rikke.helene.frølund.bjulf.01@regionh.dk |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Anesthesiology, North Zeeland Hospital | Hillerød | 3400 | Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Mar 4, 2025 |
Not provided
Not provided
Not provided
Not provided
|
| 30 days after the closed reduction |
| Readmission | Readmission within 30 days after discharge | 30 days after discharge |
| Delirium during admission | Defined as diagnose of delirium (F05.x, obtained from the diagnosis codes from the given admission) or the non-planned administration of haloperidol, olanzapine, risperidone, or quetiapine (as a surrogate for new onset delirium) | From admission to discharge up to 30 days after closed reduction |
| Acute kidney failure | Defined as serum creatinine increase of more than 25 μmol/L within a period of less than 48 hours. (As a surrogate for acute kidney failure) | Post procedure until 30 days after discharge |
| Infection requiring hospital contact | Defined as diagnosed infection (postoperative infection (T81.4), pneumonia (J13.x-J18.x), Cystitis (N30.x, N39.0), sepsis (R65.x A40.x, A41.x), C. difficile (A04.7) obtained from the diagnose codes from the given admission) or administration of antibiotic treatment (as a surrogate for in-hospital infection | Post procedure until 30 days after discharge |
| Cardiovascular complications | Defined as diagnosed arrythmia (I47.x, I48.x, I49.x), myocardial infarction (I21.x, I22.x), cerebral ischemia (I61.x, I63.x, I64.x), hemorrhage(T81), pulmonary embolism(I26.x) or deep venous thrombosis(I80.2) (obtained from the diagnosis codes from the given admission) | From admission to 30 days after discharge. |
| Aug 10, 2025 |
| Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| D013995 | Time |
| D058109 | Airway Management |
| D009466 | Neuromuscular Blocking Agents |
| ID | Term |
|---|---|
| D055585 | Physical Phenomena |
| D013812 | Therapeutics |
| D009465 | Neuromuscular Agents |
| D018373 | Peripheral Nervous System Agents |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
Not provided
Not provided